The PREPARE study team is proud to announce that the first 2,500 patients have been enrolled for the PREPARE study! The PREPARE study aims to implement pre-emptive pharmacogenetics testing, to guide drug and dose selection, across institutions in seven European countries. The study team is continuing its efforts to enrol up to 8,100 patients across these European institutions to ultimately make pre-emptive pharmacogenetics testing accessible for all European citizens.
To date, 2,500 patients have been enrolled. Of these, 990 have successfully received a pharmacogenomics test to guide drug and dose selection, and 1,527 have received standard of care.
Thank you to all patients for their participation!